For help on how to get the results you want, see our search tips.
3 results
Categories
Human Remove Human filter
Medicine
Referrals Remove Referrals filter
Referral type
Article 30 referrals Remove Article 30 referrals filter
Article 107 procedures (prior to July 2012) Remove Article 107 procedures (prior to July 2012) filter
Article 20 procedures Remove Article 20 procedures filter
Referral safety status
Yes Remove Yes filter
Referral PRAC recommendation
Risk minimisation measures Remove Risk minimisation measures filter
-
List item
Referral: Lemtrada
alemtuzumab, associated names: Lemtrada, Article 20 procedures
Status: European Commission final decision, opinion/position date: 14/11/2019, EC decision date: 16/01/2020, Last updated: 04/02/2020 -
List item
Referral: Xeljanz
tofacitinib, associated names: Xeljanz, Article 20 procedures
Status: European Commission final decision, opinion/position date: 14/11/2019, EC decision date: 31/01/2020, Last updated: 06/03/2020 -
List item
Referral: Janus kinase inhibitors (JAKi) (updated)
tofacitinib, abrocitinib, baricitinib, upadacitinib, filgotinib, associated names: Xeljanz, Cibinqo, Olumiant, Rinvoq, Jyseleca, Article 20 procedures
Status: Opinion provided by Committee for Medicinal Products for Human Use, opinion/position date: 12/01/2023, Last updated: 27/01/2023